Alliances At-A-Glance

2017

Bristol-Myers Squibb

A research collaboration to evaluate Opdivo® (nivolumab) and DS-8201 in HER2-expressing breast and bladder cancers.

detail

Max Planck Innovation and Lead Discovery Center

An agreement between Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center.

detail

Heptares Therapeutics

A drug discovery and licensing agreement with Heptares Therapeutics that is focused on a single G protein-coupled receptor (GPCR) that plays a crucial role in relieving pain.

detail

Kite Pharma

A strategic Partnership with Kite Pharma, a subsidary of Gilead Sciences, Inc. for the exclusive rights of development, manufacturing and commercialization in Japan of Kite’s cellular cancer therapy axicabtagene ciloleucel (KTE-C19) .

detail

2016

Inspirion Delivery Sciences

A collaboration to commercialize two abuse-deterrent opioid medications, MorphaBond™ ER and RoxyBond™, both of which feature a unique, patent-protected abuse-deterrent technology.

detail

AgonOx

A strategic collaboration with AgonOx, Inc. to develop an undisclosed immuno-oncology target.

detail

Zymeworks

A cross-licensing and collaboration agreement to develop proprietary cancer immuno-oncology products.

detail

Amgen

Exclusive agreement to commercialize nine biosimilars in Japan, including biosimilars of adalimumab, bevacizumab and trastuzumab.

detail

Celixir

Exclusive license in Japan to develop and market Heartcel™, a immune-modulatory progenitor (iMP) cell therapeutic agent for ischemic heart failure.

detail

2015

AstraZeneca

A Co-commercialization agreement of Movantik™, a medication indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain in US.

detail

2014

Sanford-Burnham Medical Research Institute

A comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.

detail

University of California, San Francisco

A drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases

detail

Note: This is not a complete list of Daiichi Sankyo alliances

Company Profile

As a global company, we aim to constantly extend our business activities.